Technical Analysis for ALLO - Allogene Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 27.37 -1.48% -0.41
ALLO closed down 1.48 percent on Friday, October 18, 2019, on 55 percent of normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ALLO trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
MACD Bullish Signal Line Cross Bullish 0.00%
Inside Day Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.48%
Crossed Above 20 DMA Bullish -1.48%
Up 3 Days in a Row Strength -1.48%
Up 4 Days in a Row Strength -1.48%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 3.79%
NR7 Range Contraction 3.79%

Older signals for ALLO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
ALLO Chart by TradingView
Basic chart:
Profile
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Biotechnology Cancer Life Sciences Stem Cells Cell Biology Therapy Cell Therapy Therapies For Cancer Kite Pharma Adoptive Cell Transfer
Is ALLO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Oct 18 New Gilead CFO: Let's Make a Deal
Oct 3 Moderna, Allogene Have Disappointed Investors
Sep 19 Allogene to work with Stanford on research into nucleic acid delivery system
Sep 19 Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Future Cancer Immunotherapies
Sep 19 When Will Allogene Therapeutics, Inc. (NASDAQ:ALLO) Come Back To Market?
Sep 18 Why Roche's former CEO thinks Pfizer and this cancer-fighting company may be on to something
Sep 7 Stocks To Watch: Apple, IPOs And German Auto
Sep 3 Allogene Therapeutics Announces September 2019 Investor Conference Schedule
Aug 20 Flush with cash after Gilead deal, founder pivots to real estate for his companies
Aug 9 Nektar downgraded on concerns with durability of treatment effect for NKTR-214
See more ALLO news...
Indicators
Indicator Value
52 Week High 35.55
52 Week Low 22.2
Average Volume 385,214
200-Day Moving Average 28.3301
50-Day Moving Average 27.9878
20-Day Moving Average 27.084
10-Day Moving Average 26.2
Average True Range 1.2078
ADX 20.43
+DI 21.2253
-DI 20.7132
Chandelier Exit (Long, 3 ATRs ) 30.1766
Chandelier Exit (Short, 3 ATRs ) 28.3734
Upper Bollinger Band 30.0699
Lower Bollinger Band 24.0981
Percent B (%b) 0.55
BandWidth 22.04918
MACD Line -0.606
MACD Signal Line -0.6904
MACD Histogram 0.0844
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 28.72
Resistance 3 (R3) 28.70 28.22 28.50
Resistance 2 (R2) 28.22 27.88 28.24 28.42
Resistance 1 (R1) 27.80 27.67 27.56 27.82 28.34
Pivot Point 27.32 27.32 27.21 27.34 27.32
Support 1 (S1) 26.90 26.98 26.66 26.92 26.40
Support 2 (S2) 26.42 26.77 26.44 26.32
Support 3 (S3) 26.00 26.42 26.25
Support 4 (S4) 26.02